pDC Markers for Human and Mouse Cell Identification

Plasmacytoid dendritic cells, commonly called pDCs, are identified in the lab by a set of surface proteins and internal molecules that distinguish them from other immune cells. The core human pDC markers include CD123, CD303 (also known as BDCA-2), and CD304 (BDCA-4), along with the absence of CD11c, which is present on conventional dendritic cells. Getting these markers right matters for everything from diagnosing a rare blood cancer to developing lupus drugs, yet the field has spent the past decade discovering that the markers themselves are less straightforward than once believed.

The Core Surface Markers in Humans and Mice

In human blood, pDCs are typically picked out by their bright expression of CD123 (the interleukin-3 receptor alpha chain) and their lack of CD11c, a molecule found on conventional dendritic cells. On top of that, two blood dendritic cell antigens serve as more specific tags: CD303, or BDCA-2, is a lectin receptor considered exclusive to pDCs, and CD304, or BDCA-4, is a neuropilin that also shows up on certain non-immune cells but helps narrow down the population when combined with other markers. A standard flow-cytometry approach identifies pDCs as CD123-bright, CD11c-negative cells, then confirms them with CD303 or CD304.

Mouse pDCs share some markers with their human counterparts but carry their own signature molecules as well. Both species express TLR7 and TLR9 intracellularly, along with CD45RA. Mice, however, rely on markers like CD45R (B220), Ly-6C, mPDCA-1, Siglec-H, and BST2 for pDC identification, none of which are used in human panels. This species split is worth knowing because a mouse study reporting “pDC depletion” may have targeted a different molecular handle than a human clinical trial would.

Why Accurate Identification Is Harder Than It Sounds

A recurring frustration in pDC research is that the key surface markers shift depending on what the cell is doing. CD303 and CD304 are not locked in place: their expression changes when pDCs are activated, when they migrate into tissues, or when they encounter different stimuli. A recent study examining flow-cytometry gating strategies found that BDCA-4 (CD304)-based gating has notable limitations precisely because BDCA-4 expression is dynamic and not exclusive to pDCs.¹ That means relying on a single marker can lead to either missing pDCs entirely or mistakenly counting other cell types as pDCs.

When pDCs encounter a virus like herpes simplex virus type 1, their surface receptors undergo coordinated changes across time. Receptors involved in homing to inflamed tissues, recognizing pathogens, and migrating to lymph nodes all shift in a choreographed sequence.² The practical consequence is that a panel of markers calibrated for resting pDCs in peripheral blood may not perform well for pDCs that have already been activated by infection or inflammation. Researchers designing experiments have to decide whether they want to catch pDCs at rest, in their activated state, or both, and adjust their antibody panels accordingly.

The Transcription Factor That Makes a pDC a pDC

Surface markers tell you what a cell looks like from the outside. The transcription factor E2-2 (also called TCF4) tells you why the cell looks that way. E2-2 was identified as the master regulator of pDC development: deleting it in mice blocked pDC formation entirely without affecting other immune cell lineages, and it directly switched on genes responsible for the pDC identity, including the transcription factors SpiB, IRF8, and the interferon-regulatory factor IRF7.³

E2-2 does not just flip a switch during development and walk away. It has to keep working in mature pDCs to prevent them from turning into conventional dendritic cells. When researchers deleted E2-2 from fully formed peripheral pDCs, those cells spontaneously lost their pDC markers, gained the ability to prime T cells, grew dendritic arms, and began expressing genes typical of conventional DCs.⁴ In other words, the conventional DC state appears to be the “default,” and E2-2 actively holds pDCs in their specialized identity.

Further work showed that TCF4 comes in two transcriptional forms, and both are needed for full pDC development. The longer form is expressed specifically in pDCs; when it is knocked out in mice, pDC development suffers and an unusual population of CD8-positive conventional DCs expands to fill the gap.⁵ For diagnostics, this means TCF4 is more than an academic curiosity. It has become a practical immunohistochemical marker for identifying pDC-derived tumors, as described below.

The AXL+ SIGLEC-6+ Complication

For years, any cell in blood that was CD123-bright and CD11c-negative got grouped with pDCs. Then single-cell RNA sequencing upended that classification. A landmark study revealed a new dendritic cell subset that shares surface markers with pDCs but behaves very differently: it potently activates T cells, something true pDCs barely do.⁶ These cells, called AXL+ SIGLEC-6+ dendritic cells (or AS DCs), express classical pDC markers and classical conventional DC markers simultaneously, and they can be subdivided further into CD11c-expressing and CD123-expressing subsets.

The discovery forced a redefinition. True pDCs are now considered primarily interferon-producing cells with minimal capacity to activate T cells. Some earlier findings attributed to pDCs, including certain responses to HIV, may actually have been driven by contaminating AS DCs in the same flow-cytometry gate.⁷ For anyone designing a pDC panel today, excluding AS DCs is now an essential step, and that usually means adding antibodies against AXL and SIGLEC-6 to separate the two populations cleanly.

Functional Markers Inside the Cell

The surface markers get pDCs sorted out of a blood sample. The functional markers explain why they matter immunologically. pDCs selectively express Toll-like receptor 7 and Toll-like receptor 9 within their endosomal compartments, and these two sensors are central to the cell’s purpose.⁸ TLR7 detects single-stranded RNA, the genetic material of many viruses including influenza and SARS-CoV-2. TLR9 detects unmethylated DNA motifs common in bacteria and DNA viruses. When either receptor is triggered, pDCs respond by producing massive amounts of type I interferons, particularly interferon-alpha, which rally other immune cells against the invader.

This selective TLR expression sets pDCs apart from myeloid dendritic cells, which instead carry TLR2 and TLR4 on their surfaces to detect bacterial components.⁹ TLR7 and TLR9 are not used as sorting markers in typical flow-cytometry panels because they sit inside the cell and require permeabilization to detect, which destroys live cells. But they are indispensable for understanding pDC biology and for interpreting what happens when pDC numbers or function change in disease.

pDC Markers in Cancer Diagnostics

Blastic plasmacytoid dendritic cell neoplasm, or BPDCN, is a rare and aggressive blood cancer arising from pDC precursors. Diagnosing it depends on immunophenotyping, and the standard panel has evolved as new markers have proven useful. A ten-color flow-cytometry assay developed for BPDCN workup uses CD123, HLA-DR, CD45, CD64, CD303, CD4, CD56, CD2, CD7, and CD38 to separate neoplastic pDCs from normal ones and from other leukemias.¹⁰ In this assay, neoplastic pDCs are identified as CD123-bright, HLA-DR-positive, CD64-negative, and CD45-dim.

Beyond flow cytometry, immunohistochemistry on tissue biopsies uses a complementary set of stains. One study compared diagnostic criteria and proposed a refined panel composed of TCF4, CD123, TCL1, and lysozyme for identifying BPDCN on tissue sections, addressing minor limitations in older criteria.¹¹ The inclusion of TCF4, the master transcription factor for pDC identity, is a good example of how basic biology discoveries translate into practical diagnostic tools.

CD123 does double duty in BPDCN: it helps diagnose the disease and also serves as a drug target. Tagraxofusp, the first therapy approved specifically for BPDCN, is a fusion of interleukin-3 (the natural ligand for CD123) with a truncated diphtheria toxin. The drug binds CD123 on the tumor cell surface and delivers the toxin payload inside, killing the cell.¹² When patients receive tagraxofusp, CD123-based flow-cytometry gating can be affected because the drug occupies the receptor; the ten-color panel mentioned above includes an alternative gating strategy using CD4, CD64, CD56, and HLA-DR for exactly this scenario.

pDC Markers as Therapeutic Targets in Lupus

The connection between pDCs and autoimmune disease, particularly lupus, is one of the most active areas of pDC marker research. In systemic lupus erythematosus, circulating pDCs show increased expression of interferon-regulatory factors IRF3 and IRF5, and this is associated with higher serum interferon-alpha levels.¹³ Single-cell profiling has confirmed that distinct dendritic cell clusters with upregulated TAP1, IRF7, and IFNAR1 are especially abundant in patients with systemic autoimmune disease.¹⁴

BDCA2, the pDC-specific surface receptor also known as CD303, has become a prime drug target because ligating it shuts down interferon and inflammatory mediator production. BIIB059 (litifilimab) is a humanized monoclonal antibody against BDCA2 that suppresses pDC-driven inflammation.¹⁵ A phase 2 trial tested litifilimab in patients with cutaneous lupus erythematosus to see whether blocking BDCA2 could reduce disease activity.¹⁶ Researchers have also gone further, attaching a drug payload to the anti-BDCA2 antibody to create an antibody-drug conjugate. This conjugate nearly completely blocked interferon-alpha production at both the protein and mRNA level, and unlike the naked antibody, it also suppressed a broader range of inflammatory cytokines including TNF-alpha, IL-6, and IP-10.¹⁷ The broader shutdown of inflammatory signaling through a single pDC-specific marker is a compelling proof of concept for marker-directed therapy in autoimmunity.

pDC Numbers, Markers, and Aging

One of the clearest age-related changes in human immune composition is the selective decline of pDCs. Multiple studies find that older adults have fewer circulating pDCs while their myeloid dendritic cells remain relatively stable. Crucially, the decline is not just in cell count. The pDCs that remain in older adults express less TLR7 and TLR9, the two internal sensors responsible for detecting viruses and mounting interferon responses.¹⁸ Myeloid DCs, by contrast, maintain their TLR2 and TLR4 expression across the same age span.

The TLR9 decrease with age appears particularly selective and consistent across studies.¹⁹ A study comparing elderly and young adult women found reduced circulating pDC numbers in the older group along with lower responsiveness to TLR7/8 stimulation, while serum markers of background inflammation were elevated.²⁰ This combination, fewer pDCs that respond more weakly to viral triggers alongside heightened baseline inflammation, helps explain why older adults tend to fare worse with viral infections yet simultaneously show more chronic inflammatory disease.

pDC Markers in Transplant Monitoring

After an allogeneic stem cell transplant, chronic graft-versus-host disease (cGVHD) is a major complication. Monitoring pDC levels in peripheral blood turns out to be useful for predicting who will develop it. A study measuring pDC counts and serum CXCL10 concentrations at three months post-transplant found that higher pDC numbers were independently associated with a lower risk of cGVHD. Patients with pDC counts at or above roughly 2.4 per microliter had substantially better odds, while elevated CXCL10 and a history of acute GVHD each independently raised the risk.²¹ A combined risk score using all three variables stratified patients into distinct risk groups. Here, the pDC “marker” being measured is cell count rather than a surface protein, but the underlying principle is the same: the presence or absence of pDCs in predictable quantities carries real clinical information.

pDCs in the Central Nervous System

pDCs are not confined to blood. In multiple sclerosis, researchers found that the number of pDCs in cerebrospinal fluid rises during relapses and drops during remission, even though pDC counts in peripheral blood stay the same.²² The selective accumulation in the central nervous system suggests active recruitment rather than passive spillover.

The role of pDCs in MS appears to shift over time. In animal models, pDCs promote the initial priming of inflammatory T cells that drive disease. But depleting pDCs during peak disease actually makes things worse, because by that stage the cells are producing the enzyme IDO, which activates regulatory T cells and helps dial down inflammation. The implication is that pDC markers measured in spinal fluid could theoretically serve as phase-specific biomarkers, but the timing of sampling would matter enormously. A high pDC count early in a relapse might mean something quite different from a high count during recovery.

Spatial Transcriptomics and the Future of pDC Mapping

Traditional flow cytometry detects pDC markers in isolated cell suspensions, which means you lose all information about where the cells were sitting in the tissue. Newer spatial transcriptomics platforms are changing that. A study of triple-negative breast cancer used single-cell-resolution spatial molecular imaging to measure hundreds of RNA transcripts in tumor tissue while preserving the physical layout of every cell, revealing the spatial relationships between pDCs and other immune and stromal populations within the tumor microenvironment.²³ Interferon signaling from pDCs emerged as a central feature of certain tumor immune subtypes.

A similar approach was applied to skin biopsies from dermatomyositis and cutaneous lupus, where high-resolution spatial transcriptomics profiled the complete cellular ecosystem in intact tissue sections. The method identified sixteen major skin cell types, including cell states that are notoriously hard to capture with conventional techniques, and allowed researchers to map the spatial architecture and cell-cell interactions that define the disease microenvironment.²⁴ For pDC research specifically, spatial tools let you ask not just “is the cell a pDC?” but “where is the pDC sitting, what is next to it, and what is it doing in this exact location?” As these platforms mature and their costs drop, they will likely redefine what a comprehensive pDC marker panel looks like, shifting from a handful of surface proteins measured in suspension to hundreds of transcripts measured in their native tissue context.

The PDC-E2 Overlap in Terminology

Searching for “PDC markers” occasionally pulls up an entirely unrelated topic: the pyruvate dehydrogenase complex, sometimes abbreviated PDC. The E2 subunit of this mitochondrial enzyme complex (PDC-E2) is a major autoantigen in primary biliary cholangitis, a chronic liver disease. Anti-mitochondrial antibodies targeting PDC-E2 are found in roughly 90 to 95 percent of patients with the condition and serve as a cornerstone diagnostic marker.²⁵ This abbreviation collision is worth knowing about to avoid confusion. If you encounter “PDC markers” in the context of liver disease, autoantibodies, or mitochondrial enzymes, the discussion is about the pyruvate dehydrogenase complex, not plasmacytoid dendritic cells. The same complex also shows up in cancer metabolism research, where enzymes called pyruvate dehydrogenase kinases can phosphorylate and inactivate PDC, contributing to the metabolic shift that cancer cells use to fuel their growth.²⁶